Detailed Information on Publication Record
2023
Abstract 13625: Laboratory Markers of Effective Endogenous Fibrinolysis in Intermediate-High-Risk Pulmonary Embolism
MIHALOVIC, Michal, Robert PETR, Denisa ODVODYOVÁ, Ivana MALINICOVA, Katerina PILIKOVA et. al.Basic information
Original name
Abstract 13625: Laboratory Markers of Effective Endogenous Fibrinolysis in Intermediate-High-Risk Pulmonary Embolism
Authors
MIHALOVIC, Michal, Robert PETR, Denisa ODVODYOVÁ, Ivana MALINICOVA, Katerina PILIKOVA, Michal KARPISEK, Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Zuzana MOTOVSKA
Edition
VASCULAR DISEASE AND THROMBOSIS 2023, 2023
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
30230 Other clinical medicine subjects
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.300 in 2022
RIV identification code
RIV/00216224:90249/23:00133232
ISSN
Keywords (in Czech)
Endogenous Fibrinolysis; High-Risk Pulmonary Embolism;
Keywords in English
Endogenous Fibrinolysis; High-Risk Pulmonary Embolism;
Tags
International impact
Změněno: 12/4/2024 12:54, Mgr. Michal Petr
Abstract
V originále
Introduction: Unselected therapy with fibrinolysis in intermediate risk-pulmonary embolism (iPE) is associated with an unacceptable risk of bleeding. Early identification of iPE patients on anticoagulant therapy with ineffective endogenous fibrinolysis (eFL) could optimize treatment-strategy. Aims: The study aims to determine markers of (in)effective eFL in intermediate-risk PE initially on anticoagulant therapy with UFH.
Links
| 90249, large research infrastructures |
|